Draft Bill Would Set Federal Rules for AI Health Tools
The PATIENT AI Act discussion draft would split oversight between FDA and ONC and set a payment pathway, with comments due Dec. 1.
Updated on Nov. 3, 2026 in Artificial Intelligence
Live Poll
Would you trust an insurer's AI system to help decide whether your medical care is covered?
Senate HELP Committee Chairman Bill Cassidy released a legislative discussion draft of the PATIENT AI Act, which would create a uniform federal approach to reviewing and reimbursing AI-powered health technologies. The draft is at the discussion stage and has not been enacted; stakeholder comments are due Dec. 1, 2026.
Why it matters
The draft would specify which AI-based health products fall under the FDA and which fall under the ONC, and would set regulatory scrutiny by drawing a line between higher-risk and lower-risk tools. The committee said the goal is predictable expectations for developers while keeping patient safety the priority, a move that arrives as Congress and federal agencies work through several overlapping AI health proposals.
The draft would give the FDA new authority to evaluate software modifications on a rolling basis rather than only at initial approval. It would also create a payment pathway for AI-based health tools, but the source does not give reimbursement amounts or criteria.
The players
Bill Cassidy
Republican Senator from Louisiana and chairman of the Senate HELP Committee, who released the PATIENT AI Act discussion draft.
U.S. Food and Drug Administration (FDA)
Federal agency that regulates medical devices, including AI-enabled tools, and is introducing Elsa 4.0 and the HALO data platform.
Office of the National Coordinator for Health IT (ONC)
HHS office that oversees health information technology standards and would share oversight of AI health products under the draft.
The details
The draft would sort AI health tools by risk, with higher-risk tools facing closer regulatory review than lower-risk ones. Rolling evaluation of software modifications means that an AI tool updated after approval could be reassessed over time instead of being judged only once. Stakeholders submit comments on the draft by email.
Timeline
July: The HELP Committee unanimously advanced the Health Information Privacy Reform Act.
August: The FDA sought comment on a discussion paper about regulating generative AI-enabled medical devices.
Sept. 1: Representatives introduced the Doctors Not AI Act in the House.
Oct. 19: Responses to the FDA generative AI discussion paper were due.
Dec. 1: Stakeholder comments on the PATIENT AI Act are due.
The Tech Race
The PATIENT AI Act draft follows the HHS "OneHHS" AI strategy released in December 2025 and runs alongside FDA's August discussion paper on generative AI-enabled medical devices. Together these efforts show federal agencies and Congress setting parallel rules for AI in health care.
The draft is not yet law, so no change to patient access or pricing takes effect from it now. If enacted, it would affect which AI health tools are reviewed by the FDA and which by the ONC, and how those tools are paid for.
The takeaway
The draft's risk-tiered approach and rolling FDA review of software changes are the parts to watch as the Dec. 1 comment deadline passes. Track whether the committee introduces the PATIENT AI Act as a formal bill and how the FDA's generative AI discussion paper responses shape its final oversight rules.
What happens next
Stakeholder comments on the PATIENT AI Act draft are due Dec. 1, 2026, and the Potomac Officers Club Healthcare Summit on Dec. 3 is a venue where federal health-technology officials may discuss the draft.
Further reading
For more on how federal policy is shaping AI in medicine, see Artificial Intelligence coverage.
Source note: This article includes information reported by Executive Gov.
Live Poll
Would you trust an insurer's AI system to help decide whether your medical care is covered?
